1. Landgren O, Albitar M, Ma W, et al. 2009; B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med. 360:659–67. DOI:
10.1056/NEJMoa0806122. PMID:
19213679. PMCID:
PMC7015348.

4. Siegel RL, Miller KD, Jemal A. 2015; Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. DOI:
10.3322/caac.21254. PMID:
25559415.

5. Lee H, Park HJ, Park EH, et al. 2018; Nationwide statistical analysis of lymphoid malignancies in Korea. Cancer Res Treat. 50:222–38. DOI:
10.4143/crt.2017.093. PMID:
28361523. PMCID:
PMC5784621.

6. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. 1975; Clinical staging of chronic lymphocytic leukemia. Blood. 46:219–34. DOI:
10.1182/blood.V46.2.219.219. PMID:
1139039.

8. Rozman C, Bosch F, Montserrat E. 1997; Chronic lymphocytic leukemia: a changing natural history? Leukemia. 11:775–8. DOI:
10.1038/sj.leu.2400679. PMID:
9177426.

9. Chiorazzi N, Rai KR, Ferrarini M. 2005; Chronic lymphocytic leukemia. N Engl J Med. 352:804–15. DOI:
10.1056/NEJMra041720. PMID:
15728813.

10. Hallek M, Cheson BD, Catovsky D, et al. 2018; iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 131:2745–60. DOI:
10.1182/blood-2017-09-806398. PMID:
29540348.

13. International CLL-IPI Working Group. 2016; An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 17:779–90. DOI:
10.1016/S1470-2045(16)30029-8. PMID:
27185642.
16. Kikushige Y, Ishikawa F, Miyamoto T, et al. 2011; Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 20:246–59. DOI:
10.1016/j.ccr.2011.06.029. PMID:
21840488.

18. Huntly BJ, Shigematsu H, Deguchi K, et al. 2004; MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 6:587–96. DOI:
10.1016/j.ccr.2004.10.015. PMID:
15607963.

19. So CW, Karsunky H, Passegué E, Cozzio A, Weissman IL, Cleary ML. 2003; MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell. 3:161–71. DOI:
10.1016/S1535-6108(03)00019-9. PMID:
12620410.

20. Bosch F, Dalla-Favera R. 2019; Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 16:684–701. DOI:
10.1038/s41571-019-0239-8. PMID:
31278397.

22. Deaglio S, Morra M, Mallone R, et al. 1998; Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol. 160:395–402.
23. Zupo S, Massara R, Dono M, et al. 2000; Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood. 95:1199–206. DOI:
10.1182/blood.V95.4.1199.004k21_1199_1206. PMID:
10666191.

24. Klein U, Tu Y, Stolovitzky GA, et al. 2001; Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 194:1625–38. DOI:
10.1084/jem.194.11.1625. PMID:
11733577. PMCID:
PMC2193527.

25. Seifert M, Sellmann L, Bloehdorn J, et al. 2012; Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 209:2183–98. DOI:
10.1084/jem.20120833. PMID:
23091163. PMCID:
PMC3501361.

26. Damle RN, Wasil T, Fais F, et al. 1999; Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 94:1840–7. DOI:
10.1182/blood.V94.6.1840. PMID:
10477712.

27. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. 1999; Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 94:1848–54. DOI:
10.1182/blood.V94.6.1848. PMID:
10477713.

28. Crombie J, Davids MS. 2017; IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 92:1393–7. DOI:
10.1002/ajh.24808. PMID:
28589701. PMCID:
PMC5675754.
29. Ghia P, Stamatopoulos K, Belessi C, et al. 2007; ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia. 21:1–3. DOI:
10.1038/sj.leu.2404457. PMID:
17167526.

30. Rosenquist R, Ghia P, Hadzidimitriou A, et al. 2017; Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia. 31:1477–81. DOI:
10.1038/leu.2017.125. PMID:
28439111. PMCID:
PMC5508071.

31. Crespo M, Bosch F, Villamor N, et al. 2003; ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 348:1764–75. DOI:
10.1056/NEJMoa023143. PMID:
12724482.

32. Rassenti LZ, Huynh L, Toy TL, et al. 2004; ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 351:893–901. DOI:
10.1056/NEJMoa040857. PMID:
15329427.

33. Chan AC, Iwashima M, Turck CW, Weiss A. 1992; ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell. 71:649–62. DOI:
10.1016/0092-8674(92)90598-7.
34. Kong GH, Bu JY, Kurosaki T, Shaw AS, Chan AC. 1995; Reconstitution of Syk function by the ZAP-70 protein tyrosine kinase. Immunity. 2:485–92. DOI:
10.1016/1074-7613(95)90029-2.

35. Wierda WG, O'Brien S, Wang X, et al. 2011; Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 29:4088–95. DOI:
10.1200/JCO.2010.33.9002. PMID:
21969505. PMCID:
PMC4876352.

36. Rossi D, Rasi S, Spina V, et al. 2013; Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 121:1403–12. DOI:
10.1182/blood-2012-09-458265. PMID:
23243274. PMCID:
PMC3578955.

37. Bergmann MA, Busch R, Eichhorst B, et al. 2013; Overall survival in early stage chronic lymphocytic leukemia patients with treatment indication due to disease progression: follow-up data of the CLL1 trial of the German CLL Study Group (GCLLSG). Blood. 122:4127. DOI:
10.1182/blood.V122.21.4127.4127.

38. Hallek M, Fischer K, Fingerle-Rowson G, et al. 2010; Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 376:1164–74. DOI:
10.1016/S0140-6736(10)61381-5. PMID:
20888994.

39. Fischer K, Bahlo J, Fink AM, et al. 2016; Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 127:208–15. DOI:
10.1182/blood-2015-06-651125. PMID:
26486789.

40. Tam CS, O'Brien S, Wierda W, et al. 2008; Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 112:975–80. DOI:
10.1182/blood-2008-02-140582. PMID:
18411418. PMCID:
PMC3952498.

41. Fischer K, Cramer P, Busch R, et al. 2012; Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 30:3209–16. DOI:
10.1200/JCO.2011.39.2688. PMID:
22869884.

42. Eichhorst B, Fink AM, Bahlo J, et al. 2016; First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 17:928–42. DOI:
10.1016/S1470-2045(16)30051-1. PMID:
27216274.

43. Hillmen P, Robak T, Janssens A, et al. 2015; Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 385:1873–83. DOI:
10.1016/S0140-6736(15)60027-7. PMID:
25882396.

44. Goede V, Fischer K, Busch R, et al. 2014; Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 370:1101–10. DOI:
10.1056/NEJMoa1313984. PMID:
24401022.

45. Stilgenbauer S. 2015; Prognostic markers and standard management of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2015:368–77. DOI:
10.1182/asheducation-2015.1.368. PMID:
26637745.

46. Stilgenbauer S, Schnaiter A, Paschka P, et al. 2014; Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 123:3247–54. DOI:
10.1182/blood-2014-01-546150. PMID:
24652989.

47. Mohamed AJ, Yu L, Bäckesjö CM, et al. 2009; Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 228:58–73. DOI:
10.1111/j.1600-065X.2008.00741.x. PMID:
19290921.

49. Byrd JC, Furman RR, Coutre SE, et al. 2013; Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 369:32–42. DOI:
10.1056/NEJMoa1215637. PMID:
23782158. PMCID:
PMC3772525.

50. Herman SE, Gordon AL, Hertlein E, et al. 2011; Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 117:6287–96. DOI:
10.1182/blood-2011-01-328484. PMID:
21422473. PMCID:
PMC3122947.

51. Honigberg LA, Smith AM, Sirisawad M, et al. 2010; The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 107:13075–80. DOI:
10.1073/pnas.1004594107. PMID:
20615965. PMCID:
PMC2919935.

52. Ponader S, Chen SS, Buggy JJ, et al. 2012; The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 119:1182–9. DOI:
10.1182/blood-2011-10-386417. PMID:
22180443. PMCID:
PMC4916557.

53. Byrd JC, Brown JR, O'Brien S, et al. 2014; Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 371:213–23. DOI:
10.1056/NEJMoa1400376. PMID:
24881631. PMCID:
PMC4134521.
54. Burger JA, Tedeschi A, Barr PM, et al. 2015; Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 373:2425–37. DOI:
10.1056/NEJMoa1509388. PMID:
26639149. PMCID:
PMC4722809.
55. Byrd JC, Furman RR, Coutre SE, et al. 2015; Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 125:2497–506. DOI:
10.1182/blood-2014-10-606038. PMID:
25700432. PMCID:
PMC4400288.
56. Barr PM, Robak T, Owen C, et al. 2018; Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 103:1502–10. DOI:
10.3324/haematol.2018.192328. PMID:
29880603. PMCID:
PMC6119145.

57. Byrd JC, Harrington B, O'Brien S, et al. 2016; Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 374:323–32. DOI:
10.1056/NEJMoa1509981. PMID:
26641137. PMCID:
PMC4862586.

59. Hoellenriegel J, Meadows SA, Sivina M, et al. 2011; The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 118:3603–12. DOI:
10.1182/blood-2011-05-352492. PMID:
21803855. PMCID:
PMC4916562.

60. Lannutti BJ, Meadows SA, Herman SE, et al. 2011; CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 117:591–4. DOI:
10.1182/blood-2010-03-275305. PMID:
20959606. PMCID:
PMC3694505.
61. Sharman JP, Coutre SE, Furman RR, et al. 2019; Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 37:1391–402. DOI:
10.1200/JCO.18.01460. PMID:
30995176.

62. Raedler LA. 2015; Zydelig (Idelalisib): first-in-class PI3 kinase inhibitor approved for the treatment of 3 hematologic malignancies. Am Health Drug Benefits. 8:157–62.
63. Furman RR, Sharman JP, Coutre SE, et al. 2014; Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 370:997–1007. DOI:
10.1056/NEJMoa1315226. PMID:
24450857. PMCID:
PMC4161365.
64. Jones JA, Robak T, Brown JR, et al. 2017; Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 4:e114–e26. DOI:
10.1016/S2352-3026(17)30019-4. PMID:
28257752.

66. Maddocks KJ, Ruppert AS, Lozanski G, et al. 2015; Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 1:80–7. DOI:
10.1001/jamaoncol.2014.218. PMID:
26182309. PMCID:
PMC4520535.

67. Woyach JA, Furman RR, Liu TM, et al. 2014; Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 370:2286–94. DOI:
10.1056/NEJMoa1400029. PMID:
24869598. PMCID:
PMC4144824.

68. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. 1993; bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 82:1820–8. DOI:
10.1182/blood.V82.6.1820.1820. PMID:
8104532.

69. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. 1996; Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 10:456–9.
70. Souers AJ, Leverson JD, Boghaert ER, et al. 2013; ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 19:202–8. DOI:
10.1038/nm.3048. PMID:
23291630.
71. Roberts AW, Davids MS, Pagel JM, et al. 2016; Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 374:311–22. DOI:
10.1056/NEJMoa1513257. PMID:
26639348. PMCID:
PMC7107002.

72. Coutre S, Choi M, Furman RR, et al. 2018; Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 131:1704–11. DOI:
10.1182/blood-2017-06-788133. PMID:
29305552. PMCID:
PMC5922273.

73. Jones JA, Mato AR, Wierda WG, et al. 2018; Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 19:65–75. DOI:
10.1016/S1470-2045(17)30909-9.

74. Woyach JA, Ruppert AS, Heerema NA, et al. 2018; Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 379:2517–28. DOI:
10.1056/NEJMoa1812836. PMID:
30501481. PMCID:
PMC6325637.
75. Shanafelt TD, Wang XV, Kay NE, et al. 2019; Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 381:432–43. DOI:
10.1056/NEJMoa1817073. PMID:
31365801. PMCID:
PMC6908306.
76. Moreno C, Greil R, Demirkan F, et al. 2019; Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20:43–56. DOI:
10.1016/S1470-2045(18)30788-5. PMID:
30522969.

77. Fischer K, Al-Sawaf O, Bahlo J, et al. 2019; Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 380:2225–36. DOI:
10.1056/NEJMoa1815281. PMID:
31166681.
78. Seymour JF, Kipps TJ, Eichhorst B, et al. 2018; Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 378:1107–20. DOI:
10.1056/NEJMoa1713976. PMID:
29562156.

79. Haferlach C, Dicker F, Weiss T, et al. 2010; Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. Genes Chromosomes Cancer. 49:851–9. DOI:
10.1002/gcc.20794. PMID:
20552631.

80. Pflug N, Bahlo J, Shanafelt TD, et al. 2014; Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 124:49–62. DOI:
10.1182/blood-2014-02-556399. PMID:
24797299. PMCID:
PMC4260976.

81. Malcikova J, Tausch E, Rossi D, et al. 2018; ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia. 32:1070–80. DOI:
10.1038/s41375-017-0007-7. PMID:
29467486. PMCID:
PMC5940638.

82. O'Brien S, Jones JA, Coutre SE, et al. 2016; Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 17:1409–18. DOI:
10.1016/S1470-2045(16)30212-1. PMID:
27637985.
83. Stilgenbauer S, Eichhorst B, Schetelig J, et al. 2016; Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 17:768–78. DOI:
10.1016/S1470-2045(16)30019-5. PMID:
27178240.
84. Stilgenbauer S, Eichhorst B, Schetelig J, et al. 2018; Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 36:1973–80. DOI:
10.1200/JCO.2017.76.6840. PMID:
29715056.